2 results
Approved WMOCompleted
To estimate the efficacy of erlotinib administered as a single agent to chemo-naïve NSCLC patients as determined by the non progression rate (NPR) at 8 weeks.
Approved WMOCompleted
To determine the feasibility of using ICG to optically guide the surgeon to the SLN of paediatric melanoma and sarcoma patients. The SNP is a diagnostic procedure.